Significance of pelvic lymph node dissection during radical prostatectomy in high-risk prostate cancer patients receiving neoadjuvant chemohormonal therapy
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2045-2322
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Significance of pelvic lymph node dissection during radical prostatectomy in high-risk prostate cancer patients receiving neoadjuvant chemohormonal therapy ; volume:12 ; number:1 ; day:11 ; month:6 ; year:2022 ; pages:1-9 ; date:12.2022
Scientific reports ; 12, Heft 1 (11.6.2022), 1-9, 12.2022
- Urheber
-
Iwamura, Hiromichi
Hatakeyama, Shingo
Narita, Takuma
Ozaki, Yusuke
Konishi, Sakae
Horiguchi, Hirotaka
Kodama, Hirotake
Kojima, Yuta
Fujita, Naoki
Okamoto, Teppei
Tobisawa, Yuki
Yoneyama, Tohru
Yamamoto, Hayato
Yoneyama, Takahiro
Hashimoto, Yasuhiro
Ohyama, Chikara
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1038/s41598-022-13651-x
- URN
-
urn:nbn:de:101:1-2022080706590701328569
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:31 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Iwamura, Hiromichi
- Hatakeyama, Shingo
- Narita, Takuma
- Ozaki, Yusuke
- Konishi, Sakae
- Horiguchi, Hirotaka
- Kodama, Hirotake
- Kojima, Yuta
- Fujita, Naoki
- Okamoto, Teppei
- Tobisawa, Yuki
- Yoneyama, Tohru
- Yamamoto, Hayato
- Yoneyama, Takahiro
- Hashimoto, Yasuhiro
- Ohyama, Chikara
- SpringerLink (Online service)
Ähnliche Objekte (12)
The prevalence and outcomes of pT0 disease after neoadjuvant hormonal therapy and radical prostatectomy in high-risk prostate cancer
Impact of lymph node burden on survival of high-risk prostate cancer patients following radical prostatectomy and pelvic lymph node dissection
Neoadjuvant hormonal therapy is a feasible option in laparoscopic radical prostatectomy
Extended pelvic lymph node dissection during robotic prostatectomy: antegrade versus retrograde technique
Identification of curable high-risk prostate cancer using radical prostatectomy alone: who are the good candidates for undergoing radical prostatectomy among patients with high-risk prostate cancer?
Delta radiomics analysis for prediction of intermediary- and high-risk factors for patients with locally advanced cervical cancer receiving neoadjuvant therapy
Endogenous testosterone density is an independent predictor of pelvic lymph node invasion in high-risk prostate cancer: results in 201 consecutive patients treated with radical prostatectomy and extended pelvic lymph node dissection
Correction: Extended pelvic lymph node dissection during robotic prostatectomy: antegrade versus retrograde technique
Salvage robot-assisted radical prostatectomy with pelvic lymph node dissection after cryotherapy failure
Radiotherapy for pelvic nodal recurrences after radical prostatectomy: patient selection in clinical practice
Neoadjuvant degarelix with or without apalutamide followed by radical prostatectomy for intermediate and high-risk prostate cancer: ARNEO, a randomized, double blind, placebo-controlled trial
Infectious morbidity in pediatric patients receiving neoadjuvant chemotherapy for sarcoma
The prevalence and outcomes of pT0 disease after neoadjuvant hormonal therapy and radical prostatectomy in high-risk prostate cancer
Impact of lymph node burden on survival of high-risk prostate cancer patients following radical prostatectomy and pelvic lymph node dissection
Neoadjuvant hormonal therapy is a feasible option in laparoscopic radical prostatectomy
Extended pelvic lymph node dissection during robotic prostatectomy: antegrade versus retrograde technique
Identification of curable high-risk prostate cancer using radical prostatectomy alone: who are the good candidates for undergoing radical prostatectomy among patients with high-risk prostate cancer?
Delta radiomics analysis for prediction of intermediary- and high-risk factors for patients with locally advanced cervical cancer receiving neoadjuvant therapy
Endogenous testosterone density is an independent predictor of pelvic lymph node invasion in high-risk prostate cancer: results in 201 consecutive patients treated with radical prostatectomy and extended pelvic lymph node dissection
Correction: Extended pelvic lymph node dissection during robotic prostatectomy: antegrade versus retrograde technique
Salvage robot-assisted radical prostatectomy with pelvic lymph node dissection after cryotherapy failure
Radiotherapy for pelvic nodal recurrences after radical prostatectomy: patient selection in clinical practice
Neoadjuvant degarelix with or without apalutamide followed by radical prostatectomy for intermediate and high-risk prostate cancer: ARNEO, a randomized, double blind, placebo-controlled trial
Infectious morbidity in pediatric patients receiving neoadjuvant chemotherapy for sarcoma
The prevalence and outcomes of pT0 disease after neoadjuvant hormonal therapy and radical prostatectomy in high-risk prostate cancer
Impact of lymph node burden on survival of high-risk prostate cancer patients following radical prostatectomy and pelvic lymph node dissection
Neoadjuvant hormonal therapy is a feasible option in laparoscopic radical prostatectomy
Extended pelvic lymph node dissection during robotic prostatectomy: antegrade versus retrograde technique
Identification of curable high-risk prostate cancer using radical prostatectomy alone: who are the good candidates for undergoing radical prostatectomy among patients with high-risk prostate cancer?
Delta radiomics analysis for prediction of intermediary- and high-risk factors for patients with locally advanced cervical cancer receiving neoadjuvant therapy
Endogenous testosterone density is an independent predictor of pelvic lymph node invasion in high-risk prostate cancer: results in 201 consecutive patients treated with radical prostatectomy and extended pelvic lymph node dissection
Correction: Extended pelvic lymph node dissection during robotic prostatectomy: antegrade versus retrograde technique
Salvage robot-assisted radical prostatectomy with pelvic lymph node dissection after cryotherapy failure
Radiotherapy for pelvic nodal recurrences after radical prostatectomy: patient selection in clinical practice
Neoadjuvant degarelix with or without apalutamide followed by radical prostatectomy for intermediate and high-risk prostate cancer: ARNEO, a randomized, double blind, placebo-controlled trial